Rein Therapeutics (RNTX) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on July 20, 2026, with shareholders able to vote and submit questions online.

• Shareholders of record as of May 21, 2026, are entitled to vote on key proposals, including director elections, share authorization, auditor ratification, and executive compensation.

• Proxy materials are available online, and shareholders are encouraged to vote electronically or by mail.

Voting matters and shareholder proposals

• Four main proposals: election of two Class III directors, increase in authorized common stock, ratification of CBIZ CPAs P.C. as auditor, and advisory approval of executive compensation.

• Board recommends voting FOR all proposals.

• Shareholders may submit additional proposals for the 2027 annual meeting following specified procedures.

Board of directors and corporate governance

• Board is classified into three staggered classes; two Class III directors are up for election for terms ending in 2029.

• Majority of directors are independent per Nasdaq rules; CEO is not independent.

• Board committees (Audit, Compensation, Nominating/Governance) are composed of independent directors and have defined charters.

• Corporate governance guidelines, code of ethics, insider trading, anti-hedging, and clawback policies are in place.

• Directors are expected to attend meetings and annual meetings; communication channels exist for shareholders to contact the board.